Evidence map›Paper›PMID 33168847›Full record

ArticleScientific reports2020

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors.

Alexander B Zaslavsky, M P Adams, X Cao, T Maj, J E Choi, J Stangl-Kremser, S Patel, A Putelo, S K Lee, S Nallandhighal and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Coronary artery disease and cancer: Shared risk factors, pathogenesis, and treatment effects.American heart journal plus : cardiology research and practice · 2026
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Targeting platelet-tumor cell interactions: a novel approach to cancer therapy.Medical oncology (Northwood, London, England) · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Alexander B ZaslavskyDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA. azaslavs@med.umich.edu.
M P AdamsDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
X CaoDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
T MajDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
J E ChoiRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
J Stangl-KremserDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
S PatelDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
A PuteloDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
S K LeeDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
S NallandhighalDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
A KasputisDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
A AlvaRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
M LewDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
A QinRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
R MehraDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
T M MorganDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
S S SalamiDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA.
Z ReichertRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
A UdagerRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
W ZouDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Ganesh S PalapattuDepartment of Urology, University of Michigan Medical School, 3875 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, USA. gpalapat@med.umich.edu.
University of Michigan–Ann Arbor · USA. Alfred Taubman Health Care Center · USMichigan Center for Translational Pathology · US

Funding

Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6M
NCI NIH HHS P50 CA186786
6 · The paper itself

Abstract

Strategies that interfere with the binding of the receptor programmed cell death protein-1 (PD-1) to programmed death ligand-1 (PD-L1) have shown marked efficacy against many advanced cancers, including those that are negative for PD-L1. Precisely why patients with PD-L1 negative tumors respond to PD-1/PD-L1 checkpoint inhibition remains unclear. Here, we show that platelet-derived PD-L1 regulates the growth of PD-L1 negative tumors and that interference with platelet binding to PD-L1 negative cancer cells promotes T cell-induced cancer cytotoxicity. These results suggest that the successful outcomes of PD-L1 based therapies in patients with PD-L1 negative tumors may be explained, in part, by the presence of intra-tumoral platelets. Altogether, our findings demonstrate the impact of non-cancer/non-immune cell sources of PD-L1 in the tumor microenvironment in the promotion of cancer cell immune evasion. Our study also provides a compelling rationale for future testing of PD-L1 checkpoint inhibitor therapies in combination with antiplatelet agents, in patients with PD-L1 negative tumors.

Indexed as

AdultAgedAged, 80 and overAnimalsAntineoplastic AgentsB7-H1 AntigenBlood PlateletsCell Line, TumorFemaleHumansImmune SystemImmunohistochemistryJurkat CellsMaleMiceMice, KnockoutAntineoplastic AgentsB7-H1 AntigenCD274 protein, humanCd274 protein, mousePlatelet Aggregation Inhibitors

Identifiers

PMID33168847
PMCPMC7652857
OpenAlexW3104156528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.